Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Myriad Validates Active Surveillance Threshold With Prolaris(R) for Men With Prostate Cancer

GlobeNewswire May 15, 2015

Myriad Showcases Its Pioneering Research at the 2015 ASCO Annual Meeting

GlobeNewswire May 13, 2015

Myriad to Present New Clinical Data on Prolaris(R) at the AUA 2015 Annual Meeting

GlobeNewswire May 7, 2015

Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results

GlobeNewswire May 5, 2015

Myriad to Announce Fiscal Third Quarter 2015 Financial Results on May 5, 2015

GlobeNewswire April 22, 2015

Myriad and AstraZeneca Expand Research Collaboration on Lynparza

GlobeNewswire April 1, 2015

Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting

GlobeNewswire March 20, 2015

Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting

Thomson Reuters ONE March 20, 2015

Myriad and BioMarin Expand Collaboration to Evaluate myChoice HRD(TM) as a Companion Diagnostic for Talazoparib

GlobeNewswire March 17, 2015

Quanterix' Simoa Technology to Support Myriad RBM's New Immunoassay Services

Business Wire March 5, 2015

Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform

GlobeNewswire March 5, 2015

Myriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

GlobeNewswire March 4, 2015

Myriad Genetics to Present at the Barclays Global Healthcare Conference

GlobeNewswire March 2, 2015

Myriad Board Approves $200 Million Increase in Share Repurchase Program

GlobeNewswire February 24, 2015

GeneDx, Inc. and its Parent BioReference Labs Announce Settlement of Their Cancer Gene Testing Patent Dispute with Myriad Genetics

PR Newswire February 17, 2015

Myriad Genetics to Present at the 2015 Leerink Global Healthcare Conference

GlobeNewswire February 6, 2015

Myriad Announces Retirement of Peter D. Meldrum, President and CEO

GlobeNewswire February 3, 2015

Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results

GlobeNewswire February 3, 2015

Myriad Genetics Names Johnathan M. Lancaster as Vice President of Medical Affairs

GlobeNewswire January 22, 2015

Myriad Genetics to Announce 2Q15 Financial Results on February 3, 2015

GlobeNewswire January 21, 2015
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested